Vanishing lung emphysema during chemotherapy for malignant pleural mesothelioma

We report the case of a 79-year-old man with a tobacco smoke-related left dystrophic bullous emphysema that showed a considerable recovery of the cystic abnormalities during chemotherapy for pleural malignant mesothelioma. We suggest that the disappearance of the dystrophic emphysema could be explained by the combined effect of chemotherapy and pleural disease. We briefly review the literature and we discuss the possible mechanism of this unforeseen manifestation.

Download Full-text

Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma

Journal of Clinical Pathology ◽

10.1136/jclinpath-2016-203993 ◽

2016 ◽

Vol 70 (2) ◽

pp. 179-182 ◽

Cited By ~ 7

Author(s):

Fouad Sami Alchami ◽

Richard Luther Attanoos ◽

Andrew Richard Bamber

Keyword(s):

Overall Survival ◽

Malignant Pleural Mesothelioma ◽

Malignant Mesothelioma ◽

Pleural Mesothelioma ◽

Not Otherwise Specified ◽

Prognosis Group ◽

Pathology Reports ◽

Pleural Malignant Mesothelioma ◽

Morphological Phenotype

Malignant pleural mesothelioma shows marked cytoarchitectural diversity. The aim of the study was to evaluate how morphological phenotype impacted upon overall survival. 191 cases of malignant pleural mesothelioma with available follow-up were identified, examined and classified according to histological types. The epithelioid mesotheliomas were further subdivided according to morphological subtypes: myxoid, microcystic, tubulopapillary, solid epithelioid, micropapillary and pleomorphic; biphasic mesotheliomas were divided into epithelioid component dominant and sarcomatoid component dominant; pure sarcomatoid mesotheliomas were divided into not otherwise specified, leiomyoid, desmoplastic and heterologous. All cases were confirmed by two experienced observers. Myxoid variant malignant pleural epithelioid mesothelioma was observed to have a favourable overall survival compared with pleomorphic form (p=0.00008). Pleomorphic phenotype had the worst overall survival. Morphological phenotype is an important histological factor that should be included in pathology reports to convey potential favourable prognostic subgroups of patients with mesothelioma.

Download Full-text

Mesothelium and Malignant Mesothelioma

Journal of Developmental Biology ◽

10.3390/jdb7020007 ◽

2019 ◽

Vol 7 (2) ◽

pp. 7 ◽

Cited By ~ 9

Author(s):

Emilye Hiriart ◽

Raymond Deepe ◽

Andy Wessels

Keyword(s):

Malignant Pleural Mesothelioma ◽

Malignant Mesothelioma ◽

Pleural Cavity ◽

Pleural Mesothelioma ◽

Primary Cancer ◽

Epithelial Structure

The mesothelium is an epithelial structure derived from the embryonic mesoderm. It plays an important role in the development of a number of different organs, including the heart, lungs, and intestines. In this publication, we discuss aspects of the development of the mesothelium, where mesothelial structures can be found, and review molecular and cellular characteristics associated with the mesothelium. Furthermore, we discuss the involvement of the mesothelium in a number of disease conditions, in particular in the pathogenesis of mesotheliomas with an emphasis on malignant pleural mesothelioma (MPM)—a primary cancer developing in the pleural cavity.

Download Full-text

Chemosensitivity of newly established human malignant pleural mesothelioma cells: Significant growth inhibition by amrubicin, a novel 9-aminoanthracycline, or cyclooxygenase 2 inhibitor

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.e19060 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. e19060-e19060

Author(s):

T. Hida ◽

S. Ogawa ◽

J. Park ◽

J. Shimizu ◽

...

Keyword(s):

Growth Inhibition ◽

Cell Lines ◽

Malignant Pleural Mesothelioma ◽

Malignant Mesothelioma ◽

Cyclooxygenase 2 ◽

Pleural Mesothelioma ◽

Dependent Manner ◽

Promising Therapeutic Approach ◽

Cyclooxygenase 2 Inhibitors

e19060 Background: Malignant pleural mesothelioma is asbestos-related malignancy that is highly resistant to current therapeutic modalities. Survival of patients with malignant mesothelioma is very poor, especially in advanced stage, regardless of a recent advancement of chemotherapeutical modalities of combination with cisplatin and antifolate. Methods: Eleven cell lines derived from malignant mesothelioma were established in our laboratory. Chemosensitivity of these cell lines to nine chemotherapeutic drugs (cisplatin, vinorelbine, irinotecan, gemcitabine, pemetrexed, gefitinib, erlotinib, and amrubicin and its active in vivo substance, amrubicin-13-OH) and four cyclooxygenase 2 inhibitors was tested by MTT assay. Results: Anti-cancer agents, cisplatin, vinorelbine, gemcitabine, gefitinib, or erlotinib, showed little growth inhibition, and pemetrexed and irinotecan showed modest growth inhibition in malignant mesothelioma cells, whereas amrubicin-13-OH showed strong growth inhibition. Cyclooxygenase 2 inhibitors inhibit proliferation of malignant mesothelioma cells in a dose-dependent manner: modest growth inhibition at clinically achievable low concentrations and complete growth inhibition at clinically achievable high concentrations by intrapleural instillation. In addition, enhanced growth suppression was obtained by using amrubicin-13-OH in combination with cyclooxygenase 2 inhibitor. Conclusions: Our study suggests that amrubicin can inhibit proliferation of malignant mesothelioma cells. In addition, the use of a cyclooxygenase 2 inhibitor may be a promising therapeutic approach in the treatment of mesothelioma, because previous studies indicated the presence of increased cyclooxygenase 2 expression in malignant mesothelioma, which is notoriously resistant to chemotherapy. No significant financial relationships to disclose.

Download Full-text

Multiplex Soluble Biomarker Analysis from Pleural Effusion

Biomolecules ◽

10.3390/biom10081113 ◽

2020 ◽

Vol 10 (8) ◽

pp. 1113

Author(s):

Joman Javadi ◽

Katalin Dobra ◽

Anders Hjerpe

Keyword(s):

Pleural Effusion ◽

Malignant Pleural Mesothelioma ◽

Malignant Mesothelioma ◽

Prognostic Markers ◽

Pleural Cavity ◽

Asbestos Exposure ◽

Pleural Mesothelioma ◽

Diagnostic Biomarkers ◽

Biomarker Analysis ◽

Angiopoietin 1

Malignant pleural mesothelioma (MPM) is a highly aggressive and therapy resistant pleural malignancy that is caused by asbestos exposure. MPM is associated with poor prognosis and a short patient survival. The survival time is strongly influenced by the subtype of the tumor. Dyspnea and accumulation of pleural effusion in the pleural cavity are common symptoms of MPM. The diagnostic distinction from other malignancies and reactive conditions is done using histopathology or cytopathology, always supported by immunohistochemistry, and sometimes also by analyses of soluble biomarkers in effusion supernatant. We evaluated the soluble angiogenesis related molecules as possible prognostic and diagnostic biomarkers for MPM by Luminex multiplex assay. Pleural effusion from 42 patients with malignant pleural mesothelioma (MPM), 36 patients with adenocarcinoma (AD) and 40 benign (BE) effusions were analyzed for 10 different analytes that, in previous studies, were associated with angiogenesis, consisting of Angiopoietin-1, HGF, MMP-7, Osteopontin, TIMP-1, Galectin, Mesothelin, NRG1-b1, Syndecan-1 (SDC-1) and VEGF by a Human Premixed Multi-Analyte Luminex kit. We found that shed SDC-1 and MMP-7 levels were significantly lower, whereas Mesothelin and Galectin-1 levels were significantly higher in malignant mesothelioma effusions, compared to adenocarcinoma. Galectin-1, HGF, Mesothelin, MMP-7, Osteopontin, shed SDC-1, NRG1-β1, VEGF and TIMP-1 were significantly higher in malignant pleural mesothelioma effusions compared to benign samples. Moreover, there is a negative correlation between Mesothelin and shed SDC-1 and positive correlation between VEGF, Angiopoietin-1 and shed SDC-1 level in the pleural effusion from malignant cases. Shed SDC-1 and VEGF have a prognostic value in malignant mesothelioma patients. Collectively, our data suggest that MMP-7, shed SDC-1, Mesothelin and Galectin-1 can be diagnostic and VEGF and SDC-1 prognostic markers in MPM patients. Additionally, Galectin-1, HGF, Mesothelin, MMP-7, Osteopontin, shed SDC-1 and TIMP-1 can be diagnostic for malignant cases.

Download Full-text

Management of Pleural Effusion Secondary to Malignant Mesothelioma

Journal of Clinical Medicine ◽

10.3390/jcm10184247 ◽

2021 ◽

Vol 10 (18) ◽

pp. 4247

Author(s):

Valeria Musso ◽

Cristina Diotti ◽

Alessandro Palleschi ◽

Davide Tosi ◽

Alberto Aiolfi ◽

...

Keyword(s):

Pleural Effusion ◽

Occupational Exposure ◽

Malignant Pleural Mesothelioma ◽

Malignant Mesothelioma ◽

Therapeutic Options ◽

Pleural Mesothelioma ◽

Common Cause ◽

Comprehensive View ◽

Clinical Challenge

Malignant pleural mesothelioma (MPM) is a highly aggressive pleural tumour which has been epidemiologically linked to occupational exposure to asbestos. MPM is often associated with pleural effusion, which is a common cause of morbidity and whose management remains a clinical challenge. In this review, we analysed the literature regarding the diagnosis and therapeutic options of pleural effusion secondary to mesothelioma. Our aim was to provide a comprehensive view on this subject, and a new algorithm was proposed as a practical aid to clinicians dealing with patients suffering from pleural effusion.

Download Full-text

Evaluation of pleural disease using MR and CT. . With special reference to malignant pleural mesothelioma

Acta Radiologica ◽

10.1034/j.1600-0455.2001.420511.x ◽

2001 ◽

Vol 42 (5) ◽

pp. 502-507

Author(s):

A. Knuuttila ◽

L. Kivisaari ◽

A. Kivisaari ◽

M. Palomaki ◽

P. Tervahartiala ◽

...

Keyword(s):

Special Reference ◽

Malignant Pleural Mesothelioma ◽

Pleural Mesothelioma ◽

Pleural Disease

Download Full-text

Therapeutic activity of glycoengineered anti-GM2 antibodies to malignant mesothelioma. GM2 expression in a clinical malignant pleural mesothelioma specimen determined by anti-GM2 antibody BIW-8962

Cancer Science ◽

10.1111/cas.12590 ◽

2015 ◽

Vol 106 (1) ◽

pp. January cover-January cover

Author(s):

Qi Li ◽

Wei Wang ◽

Yusuke Machino ◽

Tadaaki Yamada ◽

Kenji Kita ◽

...

Keyword(s):

Malignant Pleural Mesothelioma ◽

Malignant Mesothelioma ◽

Pleural Mesothelioma ◽

Therapeutic Activity

Download Full-text

A case from India of pleural malignant mesothelioma probably due to domestic and environmental asbestos exposure: a posthumous report

BMJ Case Reports ◽

10.1136/bcr-2018-227882 ◽

2019 ◽

Vol 12 (3) ◽

pp. e227882 ◽

Cited By ~ 1

Author(s):

Venkiteswaran Muralidhar ◽

Pankaja Raghav ◽

Prianka Das ◽

Akhil Goel

Keyword(s):

Malignant Mesothelioma ◽

Asbestos Exposure ◽

Pleural Mesothelioma ◽

Remedial Measures ◽

The West ◽

Living Quarter ◽

The Family ◽

The World ◽

Pleural Malignant Mesothelioma ◽

Close Family

India is the largest consumer of asbestos in the world. There is no report from India of mesothelioma related to asbestos. The case is a 42-year-old man who died of pleural mesothelioma. He was exposed to asbestos domestically and from the environment since birth. Two of his close family members worked in a factory that used asbestos. The living quarter of the family was within the premises of the factory. Asbestos waste was strewn on the grounds surrounding the quarters. After decades of legal battles by workers and families exposed to asbestos, Indian courts have ordered remedial measures and compensation to people, who are exposed to asbestos at work and the environment. Mesothelioma, currently in epidemic proportions in the west where asbestos production was banned in the 1990s, could rise to alarming levels in the next decades in India if the legal remedial measures are not implemented soon.

Download Full-text

Response to Chemotherapy of Brain Metastases from Malignant Pleural Mesothelioma

Tumori Journal ◽

10.1177/030089169608200509 ◽

1996 ◽

Vol 82 (5) ◽

pp. 456-458 ◽

Cited By ~ 6

Author(s):

Marco Colleoni ◽

Guido Liessi ◽

Cesare Avventi ◽

Francesca Pancheri ◽

Gigliola Sgarbossa ◽

...

Keyword(s):

Case Report ◽

Brain Metastases ◽

Malignant Pleural Mesothelioma ◽

Malignant Mesothelioma ◽

Systemic Chemotherapy ◽

Pleural Mesothelioma ◽

Complete Regression ◽

Response To Chemotherapy ◽

Intracavitary Chemotherapy ◽

Uncommon Complication

Brain metastases represent an uncommon complication in malignant pleural mesothelioma. A 55-year-old male suffering from malignant mesothelioma and pretreated with intracavitary chemotherapy and radiotherapy was submitted to systemic chemotherapy including lomustine, carboplatin, vinorelbine, fluorouracil and folates after diagnosis of bilateral cerebral deposits. The patient had an impressive response to chemotherapy, with complete regression of related symptoms. This case report represents the first on response to chemotherapy of brain metastases from mesothelioma. It points out that chemotherapy should be further explored in this subset of patients.

Download Full-text